According to Sandler, Travis & Rosenberg, the Food and Drug Administration has extended until February 5 the deadline for interested parties to, “submit comments and information to help the agency identify existing regulations and paperwork requirements that could be modified, repealed, or replaced to achieve meaningful burden reduction.”